Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Leases: 2022-2025

Historic Current Leases for Taysha Gene Therapies (TSHA) over the last 3 years, with Sep 2025 value amounting to $1.7 million.

  • Taysha Gene Therapies' Current Leases fell 8.10% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 8.10%. This contributed to the annual value of $1.9 million for FY2024, which is 14.03% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Current Leases of $1.7 million as of Q3 2025, which was down 4.03% from $1.7 million recorded in Q2 2025.
  • Taysha Gene Therapies' Current Leases' 5-year high stood at $1.9 million during Q4 2024, with a 5-year trough of $1.5 million in Q4 2022.
  • Its 3-year average for Current Leases is $1.7 million, with a median of $1.7 million in 2025.
  • As far as peak fluctuations go, Taysha Gene Therapies' Current Leases rose by 18.01% in 2024, and later dropped by 8.10% in 2025.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Current Leases stood at $1.5 million in 2022, then grew by 8.22% to $1.6 million in 2023, then rose by 14.03% to $1.9 million in 2024, then fell by 8.10% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.7 million for Q2 2025, and $1.8 million during Q1 2025.